Comparison of American Joint Committee on Cancer Pathological Stage T2a Versus T2b Urothelial Carcinoma: Analysis of Patient Outcomes in Organ Confined Bladder Cancer

2009 ◽  
Vol 181 (2) ◽  
pp. 540-546 ◽  
Author(s):  
Kelly J. Boudreaux ◽  
Peter E. Clark ◽  
William T. Lowrance ◽  
Jon A. Rumohr ◽  
Daniel A. Barocas ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Patient Outcomes ◽  
Pathological Stage ◽  
American Joint Committee

A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T2a VERSUS T2b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES IN ORGAN CONFINED BLADDER CANCER

2008 ◽  
Vol 179 (4S) ◽  
pp. 579-579
Author(s):  
Kelly J Boudreaux ◽  
Peter E Clark ◽  
William T Lowrance ◽  
Jon A Rumohr ◽  
Daniel A Barocas ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Patient Outcomes ◽  
Urothelial Cancer ◽  
Pathologic Stage ◽  
American Joint Committee

scholarly journals Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes

Cancer ◽  
2009 ◽  
Vol 115 (4) ◽  
pp. 770-775 ◽  
Author(s):  
Kelly J. Boudreaux ◽  
Sam S. Chang ◽  
William T. Lowrance ◽  
Jon A. Rumohr ◽  
Daniel A. Barocas ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Patient Outcomes ◽  
Pathologic Stage ◽  
American Joint Committee

Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer

2009 ◽  
Vol 182 (2) ◽  
pp. 459-465 ◽  
Author(s):  
Hendrik Isbarn ◽  
Pierre I. Karakiewicz ◽  
Shahrokh F. Shariat ◽  
Umberto Capitanio ◽  
Ganesh S. Palapattu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Pathological Stage

Urothelial carcinoma in the era of immune checkpoint inhibitors

Immunotherapy ◽  
2021 ◽  
Author(s):  
Nadine Khalife ◽  
Claude Chahine ◽  
Manal Kordahi ◽  
Tony Felefly ◽  
Hampig Raphael Kourie ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Invasive Disease ◽  
Line Treatment ◽  
First Line ◽  
Metastatic Urothelial Carcinoma ◽  
Muscle Invasive

Bladder cancer is the seventh most frequent cancer worldwide. The majority of patients present with nonmuscle invasive disease, while 20% of the patients are diagnosed with muscle-invasive bladder cancer. The treatment of nonmuscle invasive disease is endoscopic resection followed by intravesical adjuvant treatment for high risk patients. The standard treatment of localized muscle-invasive disease is neoadjuvant chemotherapy followed by radical cystectomy. Platinum-based chemotherapy is the first-line treatment in locally advanced or metastatic urothelial carcinoma. Immune checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma as second-line treatment or first-line in platinum-ineligible patients. Recently, pembrolizumab have been approved in BCG-refractory nonmuscle invasive bladder cancer. This review summarizes the current evidence concerning immunotherapy in the treatment of urothelial carcinoma.

scholarly journals A Case of Primary Small-Cell Carcinoma of the Bladder

2016 ◽  
Vol 9 (3) ◽  
pp. 574-579 ◽  
Author(s):  
Ashita Ono ◽  
Yosuke Hirasawa ◽  
Mitsumasa Yamashina ◽  
Naoto Kaburagi ◽  
Takashi Mima ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Small Cell Carcinoma ◽  
Distant Metastasis ◽  
Small Cell ◽  
Common Type ◽  
Cell Of Origin ◽  
Carcinoma Of The Bladder

Primary small-cell carcinoma arising from the bladder (SmCCB) is uncommon. It differs from urothelial carcinoma (UC), the most common type of bladder cancer, with respect to its cell of origin, biology, and prognosis. Biologically, prostatic SmCCB is much more aggressive than UC, and the prognosis for cases with distant metastasis is especially poor. We report here a case of primary SmCCB (cT3bN1M0) treated with radical cystectomy.

Sign in / Sign up

Export Citation Format

Share Document